Singapore – 2022
In line with its mission to empower biomedical innovation across Southeast Asia, Atlantis Bioscience Singapore played a pivotal role in 2022 by supplying critical reagents to a major core facility in Singapore, reinforcing national capabilities in cell therapy, regenerative medicine, and Advanced Therapy Medicinal Product (ATMP) development. This strategic support was provided through its regional operational network, including its Thai subsidiary, Villa Medical Center Phuket (www.thailandstemcell.com).
Singapore’s core research facilities serve as the backbone of the country’s translational and applied biomedical sciences. They provide technical platforms for hundreds of research labs, clinical trials, and biotech startups. Atlantis Bioscience’s contribution of high-quality reagents, including cell culture media, FBS, serum-free alternatives, cryopreservation buffers, and diagnostic-grade DPBS, helped maintain the precision, reproducibility, and safety required for ATMP innovation.
Building the Foundation for ATMP Innovation
Core laboratories in Singapore are critical in the development of stem cell therapy, CAR-T and NK cell platforms, and cell-free biologics such as exosomes and extracellular vesicles (EVs). These facilities operate under stringent GMP and GLP standards, requiring consistent access to validated reagents for:
- Expanding and maintaining mesenchymal stem cells (MSCs)
- Differentiating induced pluripotent stem cells (iPSCs)
- Culturing immune cells such as T cells and NK cells
- Processing patient samples for personalized medicine trials
- Developing exosome-based drug delivery systems
Atlantis Bioscience’s tailored delivery of reagents directly addressed these needs, providing a secure supply chain of GMP- and ISO-certified products essential for consistency in experimental and therapeutic settings.
What Atlantis Supplied
Atlantis Bioscience provided the following key reagents to Singapore’s national core facility:
- GMP-grade Dulbecco’s Phosphate Buffered Saline (DPBS): Used for washing stem cells and immune cells during expansion and processing.
- Fetal Bovine Serum (FBS): High-purity batches sourced with viral inactivation protocols for stem cell media supplementation.
- Xeno-free serum alternatives: To support clinical-grade stem cell and ATMP manufacturing without animal-derived components.
- Cryopreservation solutions: Optimized for cell banking, particularly for MSCs and NK cells used in clinical trials.
- MSC expansion media kits: Custom-formulated to ensure high viability, phenotype stability, and minimized senescence.
- Human platelet lysate (hPL): For xeno-free stem cell culture applications, often used in regenerative and orthopedic research.
The reagents supported multiple projects, from clinical-grade stem cell therapy trials to early-stage oncology immunotherapy pipelines and even cosmetic regenerative formulations.
Strategic Importance for Singapore’s Biotech Landscape
As one of Asia’s most advanced biotech hubs, Singapore’s success in developing next-generation ATMPs depends heavily on access to reliable biological reagents. The contribution by Atlantis Bioscience reinforced:
- The city-state’s position as a cell therapy leader in ASEAN
- Faster R&D for personalized and regenerative medicine applications
- Growth of spinouts and startups utilizing the core facility’s resources
- Regulatory compliance by offering traceable, GMP-ready reagents
- Resilience of Singapore’s biomedical supply chain post-COVID
This was not a one-time delivery, but part of an ongoing supply agreement based on trust, technical precision, and scientific collaboration.
Alignment with Atlantis’ ASEAN Vision
Atlantis Bioscience has long held a vision of creating an interconnected regenerative medicine ecosystem throughout Southeast Asia. Its investment in reagent development and distribution helps ensure that stem cell therapy, immunotherapy, and exosome-based therapeutics can scale responsibly and ethically across the region.
Its Thai subsidiary, Villa Medical Center Phuket, plays a complementary role in delivering stem cell treatment, clinical consultations, and MSC sourcing for patients and hospitals across Thailand. Together, the two arms of the company represent a bench-to-bedside model where Atlantis supports both the research and clinical ends of the biomedical spectrum.
Why Reagent Quality Matters for Stem Cell Therapy and ATMPs
For stem cell therapy and ATMPs to be effective and safe, every step of the development process—from cell expansion to cryopreservation—must be controlled and reproducible. This requires high-purity, contaminant-free reagents that can be traced to GMP-compliant manufacturing environments.
The reagents supplied by Atlantis meet these criteria, ensuring:
- Batch-to-batch consistency critical for reproducibility
- Low endotoxin and mycoplasma levels for clinical compatibility
- Complete documentation and CoA availability
- Compatibility with both manual and automated platforms
- Serum-free and xeno-free formulations for clinical translation
This degree of quality is especially critical for projects transitioning from bench research to clinical trials under Singapore HSA and international FDA-equivalent authorities.
Partnering for Progress: Long-Term Collaboration Goals
The collaboration between Atlantis Bioscience and Singapore’s core facility was not transactional. It was built on shared values and forward-thinking goals, including:
- Training programs for lab technicians in ATMP reagent handling
- Joint publication initiatives showcasing reagent performance
- Open-access protocol libraries to standardize best practices
- Early-access pilots for new Atlantis reagent lines
- Customization services for clients with specific ATMP needs
Atlantis also actively supports stem cell biobanking, NK cell expansion kits, and exosome isolation buffers—making the company a one-stop solution for Southeast Asian researchers aiming to transition from idea to implementation.
Expanding to Thailand, Malaysia, and Beyond
Following its success in Singapore, Atlantis Bioscience expanded reagent supply partnerships to:
- Thailand (via Villa Medical Center Phuket) – collaborating with Vega Clinic and Mahidol University on MSC and exosome programs
- Malaysia – supporting exosome and NK cell channels in Kuala Lumpur
- Indonesia – building GMP-compliant NK therapy platforms
- China – contract manufacturing of media and FBS for regional biotech clients
This pan-Asian model strengthens the entire supply chain for regenerative medicine, clinical trials, and commercial ATMP deployment.
Conclusion: Reagents That Empower the Future of Regenerative Medicine
By supplying Singapore’s national core facility with key reagents in 2022, Atlantis Bioscience Singapore once again affirmed its role as a trusted enabler of regenerative medicine, stem cell therapy, and ATMP development in Southeast Asia. Backed by a deep scientific foundation and a responsive distribution network, Atlantis continues to supply not just products—but the confidence that researchers and clinicians need to build the future of medicine.
As the biomedical frontier continues to evolve, partnerships like this will ensure that quality, accessibility, and innovation are always within reach.
Villa Medical Center Phuket
Villa Sukhothai, Soi Pasak 8, Choeng Thale,
Thalang District, Phuket, Thailand
Email: atlantisphuket@gmail.com
Phone/WhatsApp: +66 99 301 6969